Loading patent…
AssigneeThe Trustees of the University of Pennsylvania
InventorsDavid B. Weiner, Velpandi Ayyavoo, Sundarasamy Mahalingam, Mamata Patel
Estimating the term…
The present invention provides methods of identifying an anti-HIV compound by contacting human Vpr Interacting Protein (hVIP), or a fragment thereof known to interact with Vpr, with Vpr, or a fragment thereof known to interact with hVIP in the presence of a test compound, and comparing the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the presence of the test compound with the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the absence of the test compound. The present invention also provides transgenic non-human mammals comprising a recombinant expression vector that comprises a nucleic acid sequence that encodes hVIP.
A substantially pure protein having the amino acid sequence of SEQ ID NO:2.
An isolated nucleic acid molecule consisting of SEQ ID NO:1, or a fragment thereof having at least 10 nucleotides.
An oligonucleotide molecule comprising a nucleotide sequence complementary to a nucleotide sequence of at least 10 nucleotides of SEQ ID NO:1.
A method of making human Vpr Interacting Protein comprising:
A method of inhibiting the expression of human Vpr Interacting Protein In a cell comprising contacting said cell with an oligonucleotide complementary to SEQ ID NO:1, or a fragment thereof, whereby said oligonucleotide inhibits expression of said protein.
A method of treating an individual who has cancer comprising administering to said individual a therapeutically effective amount of an oligonucleotide complementary to SEQ ID NO:1, or a fragment thereof, whereby said oligonucleotide inhibits expression of said protein.
A method of inhibiting human Vpr Interacting Protein activity in a cell comprising contacting said cell an hVIP-binding fragment thereof.
Dependencies are inferred from the claim text.